A Phase 3 trial studied semaglutide versus placebo in type 2 diabetes
Semaglutide — Evidence
Clinical trials and publications sourced from ClinicalTrials.gov, PubMed, and FDA. Updated hourly by the automated crawler.
Claims and sources (2)
A Phase 3 trial studied semaglutide for weight management
Verified evidence (2)
STEP 1: Semaglutide for Weight Management
Phase 3 · COMPLETED · Started 2018
Efficacy and Safety of Semaglutide Once-Weekly Versus Placebo
Phase 3 · COMPLETED · Started 2014
Registered studies (50)
From the ClinicalTrials.gov record captured for this substance. Registration is not evidence of approval, efficacy, or safety.
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Incretin Microdosing for Cardiometabolic Health in People With HIV
Semaglutide (Wegovy) Treatment for Trichotillomania
Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
24-h Energy Expenditure and Anti-obesity Medication
LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients
Study of Patients Being Treated With Anti-obesity Medication
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
COMMETS- Combination MCI Metabolic Syndrome
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
ADJUnct Semaglutide Treatment in Type 1 Diabetes
Semaglutide and Intestinal Iron Absorption
Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
The Effect of Semaglutide on Pituitary Function
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes
ClinicalTrials.gov (34)
Pharmacogenetics of Response to GLP1R Agonists
Phase PHASE1 · RECRUITING · Sponsor: University of Maryland, Baltimore
Sit Less, Interact and Move More (SLIMM) 2 Study
Phase PHASE2 · RECRUITING · Sponsor: Srinvasan Beddhu
Semaglutide Therapy for Alcohol Reduction (STAR)
Phase PHASE2 · ACTIVE_NOT_RECRUITING · Sponsor: National Institute on Drug Abuse (NIDA)
Preoperative Semaglutide Prior to Radical Prostatectomy
Phase EARLY_PHASE1 · NOT_YET_RECRUITING · Sponsor: Banner Health
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
Phase PHASE4 · RECRUITING · Sponsor: Gila Therapeutics, Inc.
Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy
Phase NA · RECRUITING · Sponsor: Kazakh Academy of Nutrition
Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy
Phase NA · NOT_YET_RECRUITING · Sponsor: Phenomix Sciences
GLP-1R Agonist Treatment for Opioid Use Disorder
Phase PHASE2 · RECRUITING · Sponsor: Milton S. Hershey Medical Center
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Novo Nordisk A/S
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
Phase NA · NOT_YET_RECRUITING · Sponsor: Oelisoa Andriankaja
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Phase N/A · RECRUITING · Sponsor: Ohio State University
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
Phase PHASE2 · RECRUITING · Sponsor: Antag Therapeutics
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Phase PHASE2 · RECRUITING · Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)
Phase NA · ACTIVE_NOT_RECRUITING · Sponsor: Foundation for Atlanta Veterans Education and Research, Inc.
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Phase PHASE1 · ACTIVE_NOT_RECRUITING · Sponsor: Boehringer Ingelheim
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
Phase N/A · ENROLLING_BY_INVITATION · Sponsor: Novo Nordisk A/S
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Novo Nordisk A/S
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Novo Nordisk A/S
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Phase PHASE2 · ACTIVE_NOT_RECRUITING · Sponsor: University of California, San Diego
Semaglutide Therapy for Alcohol Reduction (STAR)
Phase PHASE2 · RECRUITING · Sponsor: National Institute on Drug Abuse (NIDA)
Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide
Phase NA · RECRUITING · Sponsor: Sheba Medical Center
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Phase PHASE3 · COMPLETED · Sponsor: Novo Nordisk A/S
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Phase N/A · RECRUITING · Sponsor: John Bauer
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
Phase PHASE2/PHASE3 · RECRUITING · Sponsor: University of Colorado, Denver
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Phase PHASE4 · ENROLLING_BY_INVITATION · Sponsor: Mayo Clinic
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder
Phase PHASE3 · NOT_YET_RECRUITING · Sponsor: VA Office of Research and Development
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Phase PHASE1 · RECRUITING · Sponsor: Novo Nordisk A/S
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Phase PHASE3 · RECRUITING · Sponsor: Novo Nordisk A/S
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
Phase N/A · RECRUITING · Sponsor: University of Alberta
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Phase PHASE3 · RECRUITING · Sponsor: Kailera
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
Phase PHASE3 · NOT_YET_RECRUITING · Sponsor: Population Health Research Institute
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
Phase NA · NOT_YET_RECRUITING · Sponsor: Hallym University
Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?
Phase NA · NOT_YET_RECRUITING · Sponsor: Knut Mai
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
Phase NA · NOT_YET_RECRUITING · Sponsor: Tianjin Medical University
PubMed (63)
Linking pediatric obesity to youth-onset type 2 diabetes: integrated longitudinal and cross-sectional evidence from population-based studies worldwide.
Clinical and experimental pediatrics · 2026 Jul 20 · DOI: 10.3345/cep.2026.01228
Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis.
Journal of clinical psychopharmacology · 2026 Jul 27 · DOI: 10.1097/JCP.0000000000002234
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).
Diabetes, obesity & metabolism · 2026 Jul 26 · DOI: 10.1111/dom.71132
Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk.
Cells · 2026 Jul 20 · DOI: 10.3390/cells15141293
GLP-1 Receptor Agonists in Cardiac Surgery: From Metabolic Drug to Potential Perioperative Cardioprotective Agent.
Journal of cardiovascular development and disease · 2026 Jul 3 · DOI: 10.3390/jcdd13070305
Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study.
Metabolites · 2026 Jul 1 · DOI: 10.3390/metabo16070460
Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations.
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026 Jul 27 · DOI: 10.1007/s00044-026-03579-6
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Diabetes, obesity & metabolism · 2026 Jul 26 · DOI: 10.1111/dom.71134
A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.
PharmacoEconomics · 2026 Jul 26 · DOI: 10.1007/s40273-026-01647-8
Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity.
Medicines (Basel, Switzerland) · 2026 Jun 28 · DOI: 10.3390/medicines13030021
Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.
Medicine · 2026 Jul 24 · DOI: 10.1097/MD.0000000000049916
Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111322
Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111363
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 Dec · DOI: 10.1080/01443615.2026.2701996
Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity.
Medicines (Basel, Switzerland) · 2026 Jun 28 · DOI: 10.3390/medicines13030021
Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.
Schizophrenia research · 2026 Jul 24 · DOI: 10.1016/j.schres.2026.06.025
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery · 2026 Jul 16 · DOI: 10.1016/j.ejvs.2026.07.037
Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
British journal of clinical pharmacology · 2026 Jul 16 · DOI: 10.1002/bcp.70711
Trends in Usage and Payments for Glucagon-Like Peptide-1 Receptor Agonists in the United States, 2017 to 2022: A Nationally Representative Repeated Cross-Sectional Study.
Journal of the American Heart Association · 2026 Jul 17 · DOI: 10.1161/JAHA.125.046302
Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.
Cureus · 2026 Jun · DOI: 10.7759/cureus.110952
Semaglutide-Induced Ischemic Colitis in A Middle-Aged Female Without Vascular Risk Factors.
European journal of case reports in internal medicine · 2026 · DOI: 10.12890/2026_006649
Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.
Frontiers in endocrinology · 2026 · DOI: 10.3389/fendo.2026.1870649
Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 Jul 17 · DOI: 10.1111/jdv.70614
Peripheral artery disease: advances in medical therapy.
European heart journal · 2026 Jul 17 · DOI: 10.1093/eurheartj/ehag516
Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.
Surgical endoscopy · 2026 Jul 17 · DOI: 10.1007/s00464-026-13147-z
Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.
JAMA health forum · 2026 Jul 2 · DOI: 10.1001/jamahealthforum.2026.2207
N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement.
Cell reports · 2026 Jul 17 · DOI: 10.1016/j.celrep.2026.117718
Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.
Current opinion in HIV and AIDS · 2026 Jul 17 · DOI: 10.1097/COH.0000000000001059
Therapeutic Benefit or Ocular Risk? Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy: Retraction.
Retina (Philadelphia, Pa.) · 2026 Aug 1 · DOI: 10.1097/IAE.0000000000004884
Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026 Jul 7 · DOI: 10.1016/j.numecd.2026.104859
Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026 Jul 16 · DOI: 10.1016/j.numecd.2026.104872
GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
Multiple sclerosis and related disorders · 2026 Jul 10 · DOI: 10.1016/j.msard.2026.107388
Semaglutide promotes angiogenesis and blood-brain barrier repair after traumatic brain injury via PDGF-BB/PDGFRβ/Ang1/Tie2/VEGF signaling pathway.
Scientific reports · 2026 Jul 18 · DOI: 10.1038/s41598-026-62312-w
Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.
Diabetes, obesity & metabolism · 2026 Jul 19 · DOI: 10.1111/dom.71076
GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.
The Journal of clinical psychiatry · 2026 Jul 15 · DOI: 10.4088/JCP.25m16212
Affordable Semaglutide in India: Expanding Access and Unanswered Questions for Children and Special Populations.
Indian pediatrics · 2026 Jul 20 · DOI: 10.1007/s13312-026-00408-2
Pre-operative concerns and post-operative satisfaction: comparing attitudes toward bariatric surgery and medication intervention for weight loss on Reddit.
Surgical endoscopy · 2026 Jul 20 · DOI: 10.1007/s00464-026-13149-x
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?
The Journal of clinical endocrinology and metabolism · 2026 Jul 21 · DOI: 10.1210/clinem/dgag290
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Annals of the American Thoracic Society · 2026 Jul 21 · DOI: 10.1093/annalsats/aaoag177
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
Biological psychiatry · 2026 Jul 21 · DOI: 10.1016/j.biopsych.2026.06.033
From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.
Translational research : the journal of laboratory and clinical medicine · 2026 Jul 21 · DOI: 10.1016/j.trsl.2026.07.008
Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
BMJ open · 2026 Jul 21 · DOI: 10.1136/bmjopen-2025-109259
Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models.
Nature communications · 2026 Jul 21 · DOI: 10.1038/s41467-026-75202-6
Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
Diabetes, obesity & metabolism · 2026 Jul 21 · DOI: 10.1111/dom.71138
Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.
Indian journal of orthopaedics · 2026 Jul · DOI: 10.1007/s43465-025-01614-z
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026 Jul 20 · DOI: 10.1177/87551225261466571
Implications of Generic Semaglutide Availability on the Cost-Effectiveness of GLP-1RA for Guideline-Indicated Patients With Type 2 Diabetes.
The Canadian journal of cardiology · 2026 Jul 22 · DOI: 10.1016/j.cjca.2026.05.013
Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.
Obesity surgery · 2026 Jul 22 · DOI: 10.1007/s11695-026-08854-4
Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
Pharmacological reports : PR · 2026 Jul 22 · DOI: 10.1007/s43440-026-00879-x
Hormonal Contraception and Initiation of Semaglutide Therapy.
JAMA network open · 2026 Jul 1 · DOI: 10.1001/jamanetworkopen.2026.24382
Can semaglutide influence tumor biomarkers? Insight from a clinical case.
Journal of food and drug analysis · 2026 Jun 15 · DOI: 10.38212/2224-6614.3594
When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning.
Fundamental & clinical pharmacology · 2026 Jul · DOI: 10.1111/fcp.70109
Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.
Biological psychiatry · 2026 Jul 22 · DOI: 10.1016/j.biopsych.2026.07.010
AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models.
Nature communications · 2026 Jul 22 · DOI: 10.1038/s41467-026-73370-z
The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East.
Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit · 2026 Jun 28 · DOI: 10.26719/2026.32.6.394
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
Clinical case reports · 2026 Jul · DOI: 10.1002/ccr3.73183
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
Journal of the Endocrine Society · 2026 Aug · DOI: 10.1210/jendso/bvag149
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
JACC. Advances · 2026 Jul · DOI: 10.1016/j.jacadv.2026.102917
Advances in proteomics research related to semaglutide: evidence from humans and animals.
Journal of endocrinological investigation · 2026 Jul 23 · DOI: 10.1007/s40618-026-02989-y
Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.
BMJ open · 2026 Jul 23 · DOI: 10.1136/bmjopen-2026-118191
Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.
Internal and emergency medicine · 2026 Jul 23 · DOI: 10.1007/s11739-026-04468-x
Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111322
Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.
Cureus · 2026 Jun · DOI: 10.7759/cureus.111363